When asked about potential cost savings with the infliximab biosimilar, nearly one-quarter of health system respondents did not believe that it represented a cost savings opportunity for their organization, according to a newly published survey in the Journal of Managed Care and Specialty Pharmacy. Conducted by Premier, Inc., a group purchasing organization, 57 US health … Continue reading A Health System Biosimilar Survey’s Implications →